ClinicalTrials.Veeva

Menu

Muscle Oxygenation, Type 1 Diabetes, and Glycated Hemoglobin (OXYDIAB)

U

University Hospital, Lille

Status

Completed

Conditions

Type 1 Diabetes

Treatments

Procedure: Dual energy X-ray absorptiometry
Procedure: Muscle biopsy
Behavioral: Incremental maximal exercise
Procedure: Accelerometry over one week
Other: Questionnaires
Dietary Supplement: Oral Glucose Tolerance Test
Procedure: Combined DLCO-DLNO

Study type

Observational

Funder types

Other

Identifiers

NCT02051504
2009_12
2009-A00746-51. (Other Identifier)

Details and patient eligibility

About

Most of the studies concerning aerobic fitness in Type 1 diabetic patients noted a relationship between impaired aerobic fitness and high glycated haemoglobin (HbA1c) levels, reflecting poor long term glycaemic control. To explain this relationship, the indirect effect of chronically high blood glucose levels on cardiovascular complications - and hence on exercise cardiovascular adaptations - are often mentioned. However, one could wonder if HbA1c could also have a direct impact on aerobic fitness patients with Type 1 diabetes. Haemoglobin glycation may increase its O2 affinity, thus limiting the O2 availability at the muscular level and impairing maximal aerobic power. Moreover, chronic hyperglycaemia might have deleterious effect on muscle mitochondrial capacity to use O2. The aim of this study is to assess the effect of Type 1 diabetes and of HbA1c level on muscular oxygen delivery and use and hence on aerobic fitness.

Full description

The current study aims at assessing the impact of Type 1 diabetes and HbA1c on muscle oxygen delivery and on muscle mitochondrial capacity. Our hypothesis is that these both steps of the oxygen cascade might be involved in the aerobic fitness impairment usually observed in poor-controlled patients.

Adults with Type 1 diabetes, aged 18-40 years, without microvascular and macrovascular diabetic complications, will be recruited among patients that regularly attend the unit of diabetology of the University Hospital of Lille and the regional hospital of Roubaix. They will be separated into 2 groups according to their glycaemic control at entrance in the study (HbA1c < 7%, HbA1c > 8%). Subsequently, two healthy control groups (checked by an OGTT) will be selected to strictly match the patients with Type 1 diabetes (age, sex, BMI, number of hours of physical activity per week, tobacco smoking). This is a cross-sectional study including 4 groups.

On their first visit, after the determination of HbA1c, all the subjects will perform at rest a DLCO/DLNO. Then they will realise an incremental exercise test to exhaustion on an electromagnetic cycle ergometer. Non-invasive measures will be performed throughout the exercise test, including gas exchange parameters (and maximal oxygen uptake), muscular and brain oxygenation (Near Infra Red Spectroscopy at vastus lateralis muscle and at prefrontal cortex). A blood sample from an arterialised ear-lobe will be taken at rest and exhaustion to determine O2 haemoglobin saturation, arterial partial pressure in O2 and CO2, haemoglobin concentration, hematocrit, and bicarbonates. Blood, from a catheter in a superficial cubital vein, will also be taken at rest, at a precise time during the exercise and immediately after the exercise to measure potential of hydrogen, bicarbonates, haemoglobin concentration, hematocrit, erythrocyte 2,3-diphosphoglycerate, and other blood markers of metabolic and hormonal adaptations to exercise. The subjects will also fill in questionnaires.

On a second visit, in a fasting state, the subjects will have a muscle biopsy at vastus lateralis using a specific needle (less than 150mg) in order to assess mitochondrial respiration capacity and endocannabinoid system activity. A venous blood sampling will allow analysing other health markers (lipid profile, insulin resistance...).

On another visit, the subjects will have a measure of body composition by Dual energy X-ray Absorptiometry and skinfold thickness.

They will also wear an accelerometer over one week and fill in a diet questionnaire over 3 days.

Enrollment

79 patients

Sex

All

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Patients with Type 1 diabetes (duration of Type 1 diabetes > 1 year and < 20 years)
  • Healthy subjects

Exclusion criteria

Exclusion Criteria for patients with Type 1 diabetes:

  • Maturity onset diabetes of the young, mitochondrial diabetes, Type 2 diabetes
  • Macro or microvascular complications of diabetes

Exclusion Criteria for healthy controls :

• Diabetes (Glycaemia > 11 mmol/L two hours after the OGTT)

Exclusion Criteria for all subjects :

  • Obesity (Body Mass Index > 30 kg/m2)
  • Contra-indication to maximal exercise
  • Pregnant or breast-feeding women
  • Other chronic disease than diabetes
  • Muscle or articular problems

Trial design

79 participants in 4 patient groups

Type 1 diabetes, HbA1c <7%
Description:
Patients with Type 1 diabetes and adequate glycemic control: HbA1c \<7% at the entrance in the study. Intervention: Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry
Treatment:
Procedure: Muscle biopsy
Procedure: Dual energy X-ray absorptiometry
Behavioral: Incremental maximal exercise
Procedure: Combined DLCO-DLNO
Procedure: Accelerometry over one week
Other: Questionnaires
Type 1 diabetes, HbA1c >8%
Description:
Patients with Type 1 diabetes and inadequate glycemic control: HbA1c \>8% at the entrance in the study. Intervention: Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry
Treatment:
Procedure: Muscle biopsy
Procedure: Dual energy X-ray absorptiometry
Behavioral: Incremental maximal exercise
Procedure: Combined DLCO-DLNO
Procedure: Accelerometry over one week
Other: Questionnaires
Healthy controls, Groupe 1
Description:
Healthy controls for patients with Type 1 diabetes and adequate glycemic control matched on age, sex, body composition and physical activity level. Intervention: Oral Glucose Tolerance Test Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry
Treatment:
Procedure: Muscle biopsy
Procedure: Dual energy X-ray absorptiometry
Behavioral: Incremental maximal exercise
Procedure: Combined DLCO-DLNO
Dietary Supplement: Oral Glucose Tolerance Test
Procedure: Accelerometry over one week
Other: Questionnaires
Healthy controls, Group 2
Description:
Healthy controls for patients with Type 1 diabetes and inadequate glycemic control matched on age, sex, body composition and physical activity level. Intervention: Oral Glucose Tolerance Test Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry
Treatment:
Procedure: Muscle biopsy
Procedure: Dual energy X-ray absorptiometry
Behavioral: Incremental maximal exercise
Procedure: Combined DLCO-DLNO
Dietary Supplement: Oral Glucose Tolerance Test
Procedure: Accelerometry over one week
Other: Questionnaires

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems